Skip to content
Kalpvruksh Markets
Offline Log in

SUDEEPPHRMNSEOffline

SUDEEP PHARMA · INE0QPI01025 · Small Cap · #663
1,190.30+73.60 (+6.59%)last close · 05 Nov 2026
Prev close
1,116.70
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹7,434 cr
52-week range · to 05 Nov 20265301,344.2

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

SUDEEPPHRM is 11% below its 52-week high, above its 200-day average — a Small Cap company, #663 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 50 / 200-day averages · 11% below its 52-week high
  • +26.9% vs Nifty 500
  • traded value 0.9× usual · delivery 44% vs 49% usual
  • FPI +1.1 pp · DII −1.6 pp · MF schemes in Sept 2026: 9 bought, 6 cut · no promoter pledge · quarter ended 2026-09-30
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹7,434 cr
Rank
#663
Cap band
Small Cap
Nearest cut-off — Mid / Small
−78.26% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
1.4×
median 1,35,862
Delivered
1,84,814
Of volume
44%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+5.3%−0.5 pts—
1 month+2.8%−1.8 pts—
3 months+24.1%+26.9 pts—
6 months+76.4%+75.7 pts—
1 year———

Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+13.4%
above
vs 50-day average
+4.8%
above
vs 200-day average
+42.8%
above
ATR (14)
5.8%
typical daily range
Volatility
61%
1 month, annualised
Beta
1.05
vs Nifty 500, 1 year
Traded value
0.9×
vs usual
Delivery
44%
usual 49%
From the 52-week high
−11.4%
place in range 81% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters76.2%76.2%76.2%76.2%
FPI1.7%1.6% −0.11.8% +0.32.9% +1.1
Mutual funds5.7%6.2% +0.55.5% −0.77.4% +2.0
Other DII11.9%11.9%10.2% −1.76.6% −3.6
Individuals3.3%3.1% −0.24.9% +1.85.4% +0.5
Others1.3%1.1% −0.21.5% +0.41.4% −0.1

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Dec 25 noneMar 26 noneJun 26 noneSep 26 none

Holders

Sep 26

All shareholders
40,465
Individuals
38,735

Indian passive funds’ stake

2026-06-30

Of free float
0.26%
Of all shares
0.06%
Schemes
7
Days to unwind
0.2
at 100% of volume

69,322 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
28
7 index · 21 active
Bought more
6
Sold some
5
FundSharesChangeDid
Motilal Oswal Nifty Microcap 250 Index Fund-Reg(G)Index+723+1.1%bought
Axis Multi Asset Allocation Fund-Reg(G)Active−20,631−31.6%sold
UTI Healthcare Fund-Reg(IDCW)Active−1,14,631−30.1%sold
WOC Pharma and Healthcare Fund-Reg(G)Active−18,386−29.2%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 26321860+0.2%₹957 cr
Aug 26311420+1.1%₹958 cr
Jul 26306161+32.7%₹690 cr
Jun 26252532−7.6%₹501 cr
May 26252150+2.3%₹474 cr
Apr 26230150−1.9%₹442 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Sudeep Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
    05 Aug 2026
  • Board outcome
    Sudeep Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 26, 2026.
    29 Jun 2026
  • Board outcome
    Sudeep Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on May 21, 2026.
    22 May 2026
  • Board outcome
    Outcome of Board Meeting-XBRL SUDEEP PHARMA LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 21-May-2026 for Dividend
    22 May 2026
  • Board outcome
    Sudeep Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
    21 May 2026
  • Bulk deal: BUY
    11,76,472 at ₹850 — GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIO
    04 Aug 2026
  • Bulk deal: SELL
    6,14,112 at ₹850 — NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES III
    04 Aug 2026
  • Block deal: BUY
    11,76,472 at ₹850 — GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIO
    04 Aug 2026
  • Block deal: SELL
    6,14,112 at ₹850 — NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES III
    04 Aug 2026

Latest shown; 10 in six months on all disclosures.

SUDEEPPHRM: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
EarlierDividend₹1.5Final23 Jul 202623 Jul 2026

1 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.